iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/39035353/
Beyond antibiotics: CRISPR/Cas9 triumph over biofilm-associated antibiotic resistance infections - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 5:14:1408569.
doi: 10.3389/fcimb.2024.1408569. eCollection 2024.

Beyond antibiotics: CRISPR/Cas9 triumph over biofilm-associated antibiotic resistance infections

Affiliations
Review

Beyond antibiotics: CRISPR/Cas9 triumph over biofilm-associated antibiotic resistance infections

Azna Zuberi et al. Front Cell Infect Microbiol. .

Abstract

A complex structure known as a biofilm is formed when a variety of bacterial colonies or a single type of cell in a group sticks to a surface. The extracellular polymeric compounds that encase these cells, often consisting of proteins, eDNA, and polysaccharides, exhibit strong antibiotic resistance. Concerns about biofilm in the pharmaceutical industry, public health, and medical fields have sparked a lot of interest, as antibiotic resistance is a unique capacity exhibited by these biofilm-producing bacteria, which increases morbidity and death. Biofilm formation is a complicated process that is controlled by several variables. Insights into the processes to target for the therapy have been gained from multiple attempts to dissect the biofilm formation process. Targeting pathogens within a biofilm is profitable because the bacterial pathogens become considerably more resistant to drugs in the biofilm state. Although biofilm-mediated infections can be lessened using the currently available medications, there has been a lot of focus on the development of new approaches, such as bioinformatics tools, for both treating and preventing the production of biofilms. Technologies such as transcriptomics, metabolomics, nanotherapeutics and proteomics are also used to develop novel anti-biofilm agents. These techniques help to identify small compounds that can be used to inhibit important biofilm regulators. The field of appropriate control strategies to avoid biofilm formation is expanding quickly because of this spurred study. As a result, the current article addresses our current knowledge of how biofilms form, the mechanisms by which bacteria in biofilms resist antibiotics, and cutting-edge treatment approaches for infections caused by biofilms. Furthermore, we have showcased current ongoing research utilizing the CRISPR/Cas9 gene editing system to combat bacterial biofilm infections, particularly those brought on by lethal drug-resistant pathogens, concluded the article with a novel hypothesis and aspirations, and acknowledged certain limitations.

Keywords: CRSISR/Cas9; antibiotic resistance; bacteria; biofilm; gene editing; infections.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Regulatory pathways controlling biofilm bacterial resistance: Quorum sensing or multispecies interaction, efflux pumps, response to stress and constraints in nutrients, reducing penetration or preventing access and mutations or altering cell walls.
Figure 2
Figure 2
Schematic representation showing treatment modalities against biofilm-mediated infections: Photodynamic therapy (PDT), Small molecules as polypeptides or quorum sensing inhibitors, Antibiotics, Hydrogels, nanoparticles and the CRISPR/Cas9.

Similar articles

Cited by

References

    1. Adam B., Baillie G. S., Douglas L. J. (2002). Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. J. Med. Microbiol. 51, 344–349. doi: 10.1099/0022-1317-51-4-344 - DOI - PubMed
    1. Ahmad N., Ali S. M., Khan A. U. (2017). First reported New Delhi metallo-β-lactamase-1-producing Cedecea lapagei. Int. J. Antimicrobial Agents 49, 118–119. doi: 10.1016/j.ijantimicag.2016.10.001 - DOI - PubMed
    1. Ahmad N., Khalid S., Ali S. M., Khan A. U. (2018). Occurrence of blaNDM variants among enterobacteriaceae from a neonatal intensive care unit in a Northern India hospital. Front. Microbiol. 9. doi: 10.3389/fmicb.2018.00407 - DOI - PMC - PubMed
    1. Ahmad N., Joji R. M., Shahid M. (2023). Evolution and implementation of One Health to control the dissemination of antibiotic-resistant bacteria and resistance genes: A review. Front. Cell. Infection Microbiol. 12. doi: 10.3389/fcimb.2022.1065796 - DOI - PMC - PubMed
    1. Ali F., Sangwan P. L., Koul S., Pandey A., Bani S., Abdullah S. T., et al. . (2012). 4-Epi-pimaric acid: a phytomolecule as a potent antibacterial and anti-biofilm agent for oral cavity pathogens. Eur. J. Clin. Microbiol. Infect. Dis. 31, 149–159. - PubMed

Substances

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.